Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Inspections To Focus On Sterile Rx, New Facilities In FY 2003

Executive Summary

FDA will continue to emphasize inspection of sterile manufacturing facilities in fiscal year 2003, Division of Manufacturing & Product Quality Director Joseph Famulare said Dec. 11

You may also be interested in...



FDA Inspections To Target 55% Of “High-Risk” Manufacturers In FY 2004

FDA inspections will target 55% of "high-risk" drug manufacturers during fiscal year 2004

FDA Inspections To Target 55% Of “High-Risk” Manufacturers In FY 2004

FDA inspections will target 55% of "high-risk" drug manufacturers during fiscal year 2004

FDA GMP Initiative Shifts Warning Letter Review Back To Agency Centers

The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of an FDA initiative to create a risk-based approach to pharmaceutical manufacturing

Related Content

UsernamePublicRestriction

Register

PS040940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel